Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | PPIA | P62937 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | CDC25B | P30305 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27158539 | 0.91 | KMT2A (0.55) | MRGPRX4SMN1; SMN2HPGDNPC1RAB9A | |
| SCHEMBL13379254 | 0.89 | MAOB (0.47) | MRGPRX4PPIASMN1; SMN2HPGDNPC1 | |
| SCHEMBL1501701 | 0.87 | ELANE (0.45) | PPIASMN1; SMN2HPGDNPC1RAB9A | |
| SCHEMBL8180897 | 0.87 | PPIA (0.44) | MRGPRX4PPIASMN1; SMN2HPGDNPC1 | |
| SCHEMBL20975261 | 0.87 | HPGD (0.60) | MRGPRX4PPIASMN1; SMN2HPGDNPC1 | |
| SCHEMBL6206631 | 0.86 | MAOB (0.51) | MRGPRX4SMN1; SMN2HPGDNPC1RAB9A | |
| SCHEMBL8133701 | 0.84 | MRGPRX4 (0.49) | MRGPRX4PPIASMN1; SMN2HPGDNPC1 | |
| SCHEMBL28633934 | 0.84 | KDM4E (0.56) | MRGPRX4CA12CA1CA2CA7 | |
| SCHEMBL6959477 | 0.84 | MRGPRX4 (0.66) | MRGPRX4SMN1; SMN2HPGDNPC1RAB9A | |
| SCHEMBL30696120 | 0.84 | MRGPRX4 (0.66) | MRGPRX4SMN1; SMN2HPGDNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018178226-A1 | MCL-1 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2018-10-04 | — | — | WO | disclosed |
| EP-2168952-B1 | MORPHOLINE DERIVATIVES AS RENIN INHIBITORS | MITSUBISHI TANABE PHARMA CORP (JP) | 2017-02-15 | — | — | EP | disclosed |
| EP-2168952-B1 | MORPHOLINE DERIVATIVES AS RENIN INHIBITORS | MITSUBISHI TANABE PHARMA CORP (JP) | 2017-02-15 | — | — | EP | disclosed |
| US-8975252-B2 | Morpholine derivative | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2015-03-10 | — | — | US | disclosed |
| US-8975252-B2 | Morpholine derivative | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2015-03-10 | — | — | US | disclosed |
| US-8975252-B2 | Morpholine derivative | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2015-03-10 | — | — | US | disclosed |
| CN-101679324-B | Morpholine derivatives | MITSUBISHI TANABE PHARMA CORP | 2012-10-03 | — | — | CN | disclosed |
| US-20100240644-A1 | MORPHOLINE DERIVATIVE | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2010-09-23 | — | — | US | disclosed |
| US-20100240644-A1 | MORPHOLINE DERIVATIVE | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2010-09-23 | — | — | US | disclosed |
| US-20100240644-A1 | MORPHOLINE DERIVATIVE | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2010-09-23 | — | — | US | disclosed |
| EP-2168952-A1 | MORPHOLINE DERIVATIVE | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-03-31 | — | — | EP | disclosed |
| CN-101679324-A | Morpholine derivatives | MITSUBISHI TANABE PHARMA CORP | 2010-03-24 | — | — | CN | disclosed |
| US-20060079533-A1 | Methods of treating alzheimer's disease | NIEMAN JAMES A | 2006-04-13 | — | — | US | disclosed |
| WO-2002076440-A2 | METHODS OF TREATING ALZHEIMER'S DISEASE WITH PIPERIDIN DERIVATES | ELAN PHARMACEUTICALS, INC. (US) | 2002-10-03 | — | — | WO | disclosed |
| US-6150526-A | Piperidine derivative having renin inhibiting activity | HOFFMANN-LA ROCHE INC. (US) | 2000-11-21 | — | — | US | disclosed |
| US-6051712-A | PREVENTION OF HIGH BLOOD PRESSURE AND CARDIAC INSUFFICIENCY, AS WELL AS GLAUCOMA, CARDIAC INFARCT, KIDNEY INSUFFICIENCY AND RESTENOSIS | HOFFMANN-LA ROCHE INC. (US) | 2000-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240644-A1 | MORPHOLINE DERIVATIVE | REN, AGTR1, AGTR2 | MRGPRX4 234/4885CA12 4571/4885CA1 4330/4885 |
| US-20060079533-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, PSEN2 | MRGPRX4 914/4885CA12 2820/4885CA1 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.